Literature DB >> 23518356

Off-label use of drugs and devices in the neuroendovascular suite.

M M Abdihalim1, A E Hassan, A I Qureshi.   

Abstract

SUMMARY: The off-label use of drugs and devices in neuroendovascular procedures is common. Neurointerventionalists should be well aware of the level of evidence available in support of the off-label use of drugs and devices in their practice and some of the potential adverse events associated with them. These uses are categorized as I or II if they have been evaluated as primary or ancillary interventions in prospective trials/registries of neuroendovascular procedures and III if they were evaluated in case series. Category IV use is based on evaluation as primary or ancillary interventions in prospective trials/registries of non-neuroendovascular procedures. Physicians are allowed to use off-label drugs and procedures if there is strong evidence that they are beneficial for the patient. The neurointerventional professional societies agree that off-label use of drugs and devices is an important part of the specialty, but practicing providers should base their decisions on sound evidence when using such drugs and devices.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23518356      PMCID: PMC7964838          DOI: 10.3174/ajnr.A3447

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  115 in total

Review 1.  Utility of intravascular ultrasound in intracranial and extracranial neurointerventions: experience at University at Buffalo Neurosurgery-Millard Fillmore Gates Circle Hospital.

Authors:  Peter Kan; Maxim Mokin; Adib A Abla; Jorge L Eller; Travis M Dumont; Elad I Levy; Adnan H Siddiqui
Journal:  Neurosurg Focus       Date:  2012-01       Impact factor: 4.047

2.  Direct thrombin inhibitors.

Authors:  Marcello Di Nisio; Saskia Middeldorp; Harry R Büller
Journal:  N Engl J Med       Date:  2005-09-08       Impact factor: 91.245

3.  Complication rates using balloon-expandable and self-expanding stents for the treatment of intracranial atherosclerotic stenoses : analysis of the INTRASTENT multicentric registry.

Authors:  Wiebke Kurre; Friedhelm Brassel; Roland Brüning; Jan Buhk; Bernd Eckert; Susanna Horner; Michael Knauth; Thomas Liebig; Jana Maskova; Dirk Mucha; Vojtech Sychra; Matthias Sitzer; Michael Sonnberger; Marc Tietke; Johannes Trenkler; Bernd Turowski; Joachim Berkefeld
Journal:  Neuroradiology       Date:  2011-01-11       Impact factor: 2.804

4.  Embolization of dural cavernous fistulas via superior ophthalmic vein approach.

Authors:  D Quiñones; G Duckwiler; P Y Gobin; R A Goldberg; F Viñuela
Journal:  AJNR Am J Neuroradiol       Date:  1997-05       Impact factor: 3.825

5.  Endovascular treatment of symptomatic intracranial arterial stenosis: six-year experience in a single-center series of 42 consecutive patients with acute and mid-term results.

Authors:  Vincent Costalat; Igor Lima Maldonado; Jean-Baptiste Zerlauth; Nicolas Menjot; Carlos Riquelme; Paolo Machi; Jean-François Vendrell; Alain Bonafé
Journal:  Neurosurgery       Date:  2010-12       Impact factor: 4.654

6.  Balloon angioplasty for the treatment of vasospasm: results of first 50 cases.

Authors:  J M Eskridge; W McAuliffe; J K Song; A V Deliganis; D W Newell; D H Lewis; M R Mayberg; H R Winn
Journal:  Neurosurgery       Date:  1998-03       Impact factor: 4.654

7.  Abciximab is a safe rescue therapy in thromboembolic events complicating cerebral aneurysm coil embolization: single center experience in 42 cases and review of the literature.

Authors:  Thorsten Ries; Susanne Siemonsen; Ulrich Grzyska; Hermann Zeumer; Jens Fiehler
Journal:  Stroke       Date:  2009-03-19       Impact factor: 7.914

8.  Endovascular management of dural arteriovenous fistulas of the transverse and sigmoid sinus in 150 patients.

Authors:  M Kirsch; T Liebig; D Kühne; H Henkes
Journal:  Neuroradiology       Date:  2009-04-08       Impact factor: 2.804

9.  Stenting of symptomatic M1 stenosis of middle cerebral artery: an initial experience of 40 patients.

Authors:  Wei-Jian Jiang; Yong-Jun Wang; Bin Du; Su-Xiang Wang; Gui-Hong Wang; Min Jin; Jian-Ping Dai
Journal:  Stroke       Date:  2004-05-06       Impact factor: 7.914

10.  Endarterectomy Versus Angioplasty in Patients with Symptomatic Severe Carotid Stenosis (EVA-3S) trial: results up to 4 years from a randomised, multicentre trial.

Authors:  Jean-Louis Mas; Ludovic Trinquart; Didier Leys; Jean-François Albucher; Hervé Rousseau; Alain Viguier; Jean-Pierre Bossavy; Béatrice Denis; Philippe Piquet; Pierre Garnier; Fausto Viader; Emmanuel Touzé; Pierre Julia; Maurice Giroud; Denis Krause; Hassan Hosseini; Jean-Pierre Becquemin; Grégoire Hinzelin; Emmanuel Houdart; Hilde Hénon; Jean-Philippe Neau; Serge Bracard; Yannick Onnient; Raymond Padovani; Gilles Chatellier
Journal:  Lancet Neurol       Date:  2008-09-05       Impact factor: 44.182

View more
  3 in total

1.  Catheter-Based Transepidural Approach to Cervical and Thoracic Posterior and Perineural Epidural Spaces: A Cadaveric Feasibility Study.

Authors:  Adnan I Qureshi; Mushtaq H Qureshi; Ahmed A Malik; Asif A Khan; Amna Sohail; Aveen Saed; Vikram Jadhav
Journal:  J Vasc Interv Neurol       Date:  2015-05

2.  Availability of endovascular therapies for cerebrovascular disease at primary stroke centers.

Authors:  Mark J Alberts; Jean Range; William Spencer; Vicki Cantwell; M J Hampel
Journal:  Interv Neuroradiol       Date:  2016-11-30       Impact factor: 1.610

3.  Management of a decompensated acute-on-chronic intracranial venous sinus thrombosis.

Authors:  Carmen Serna Candel; Victoria Hellstern; Tania Beitlich; Marta Aguilar Pérez; Hansjörg Bäzner; Hans Henkes
Journal:  Ther Adv Neurol Disord       Date:  2019-12-24       Impact factor: 6.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.